Skip to content
New cancer vaccine delivers stunning result against one of the deadliest skin cancers
Fox News — PRIOR COVERAGE, NOT THE AUG 19 PHASE 3 STORY (June 2, 2026 Phase 2b five-year follow-up). Context only. ·
back to the auditNOT the current story. Byline: Angelica Stabile; published June 2, 2026. This is Phase 2b (KEYNOTE-942) five-year follow-up data presented at ASCO May 27, 2026. VERBATIM fragments: lead "A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period."; "was found to reduce the risk of melanoma recurrence or death by 49% compared to pembrolizumab alone."; Moderna's Kyle Holen: "We continue to invest in our platform in oncology because of encouraging outcomes like these"; Merck's Dr. Marjorie Green called the result "a meaningful milestone." 157 patients. Use ONLY to evidence Fox News's prior framing of the 49% figure as a stunning result on the OLD dataset — never as a Phase 3 span.